163 related articles for article (PubMed ID: 38058118)
41. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
[TBL] [Abstract][Full Text] [Related]
42. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
43. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
44. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
45. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
46. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas.
Wolfson AH; Wolfson DJ; Sittler SY; Breton L; Markoe AM; Schwade JG; Houdek PV; Averette HE; Sevin BU; Penalver M
Gynecol Oncol; 1994 Jan; 52(1):56-62. PubMed ID: 8307502
[TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F; Dai X; Chen H; Hu X; Wang Y
BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
[TBL] [Abstract][Full Text] [Related]
48. [Cytomorphological diagnosis of nonepithelial tumors of the uterus].
Novik VI
Arkh Patol; 1985; 47(8):45-52. PubMed ID: 3000322
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
50. [Uterine sarcomas: clinical and therapeutic aspects (10 cases)].
Hassini A; Khemiri B; Sfar E; Chelly D; Chennoufi MB; Chelly H
J Gynecol Obstet Biol Reprod (Paris); 2006 Jun; 35(4):348-55. PubMed ID: 16940904
[TBL] [Abstract][Full Text] [Related]
51. [Clinical and morphologic diagnosis of uterine sarcoma].
Bokhman IaV; Urmancheeva AF; Neustadt EL; Kutusheva GF
Vopr Onkol; 1998; 44(2):175-80. PubMed ID: 9615822
[TBL] [Abstract][Full Text] [Related]
52. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
53. A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China.
Li D; Yin N; Du G; Wang S; Xiao Z; Chen J; Chen W
Int J Biol Sci; 2020; 16(3):388-395. PubMed ID: 32015676
[TBL] [Abstract][Full Text] [Related]
54. Nestin: A biomarker of aggressive uterine cancers.
Hope ER; Mhawech-Fauceglia P; Pejovic T; Zahn CM; Wang G; Conrads TP; Larry Maxwell G; Hamilton CA; Darcy KM; Syed V
Gynecol Oncol; 2016 Mar; 140(3):503-11. PubMed ID: 26718725
[TBL] [Abstract][Full Text] [Related]
55. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.
Coosemans A; Van Calster B; Verbist G; Moerman P; Vergote I; Van Gool SW; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):302-8. PubMed ID: 21734473
[TBL] [Abstract][Full Text] [Related]
56. Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
Hum Pathol; 2021 Oct; 116():12-21. PubMed ID: 34271067
[TBL] [Abstract][Full Text] [Related]
57. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
[TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of parity in 493 uterine sarcoma patients.
Albrektsen G; Heuch I; Wik E; Salvesen HB
Int J Gynecol Cancer; 2009 Aug; 19(6):1062-7. PubMed ID: 19820369
[TBL] [Abstract][Full Text] [Related]
59. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis.
Lim JJ; Kang S; Lee MR; Pai HK; Yoon HJ; Lee JI; Hong SP; Lim CY
J Oral Pathol Med; 2003 Oct; 32(9):552-61. PubMed ID: 12969230
[TBL] [Abstract][Full Text] [Related]
60. [Clinicopathological features of malignant mixed mesodermal tumor: analysis of 50 cases].
Ding XH; Ma ZY; Wang YF; Dou FX; Yuan J; Tian X; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1008-1013. PubMed ID: 34496490
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]